Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 214

The DOI matches its Crossref record.

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegaly

Open access
Mercado, Moises, Borges, Fatima, Bouterfa, Hakim, Chang, Tien‐Chun, Chervin, Alberto, Farrall, Andrew J., Patocs, Attila, Petersenn, Stephan, Podoba, Jan, Safari, Mitra, Wardlaw, Joanna, on behalf of the SMS995B2401 Study Group · 2007 · Clinical Endocrinology

Abstract

Summary: Objective To evaluate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of acromegaly. Design and patients Ninety‐eight previously untreated acromegalics were recruited into this prospective multicentre study. A total of 68 patients successfully completed 48 weeks of the study period, received 12 doses of octreotide LAR 10–30 mg every 4 weeks, and constituted the population used for this analysis. Measurements and results A clinically relevant reduction (i.e. to ≤ 5 µg/l) in mean GH (mGH) was recorded in 72% of patients after 24 weeks of treatment, and 42% reached a ‘safe’ GH value (≤ 2·5 µg/l). At week 48, 16 more patients were considered partial GH responders (GH > 2·5 µg/l and ≤ 5 µg/l) and 44% had reached a GH level ≤ 2·5 µg/l. IGF‐1 levels normalized in 38% and 34% of patients after 24 and 48 weeks of treatment, respectively. At study completion, 10 patients (14·7%) who had not normalized their IGF‐1 levels had achieved at least a 50% decrement in this marker. In eight microadenoma patients, tumour volume decreased from a mean baseline level of 298 ± 145 mm 3 to 139 ± 94 mm 3 after 24 weeks and to 99 ± 70 mm 3 after 48 weeks of therapy. In 60 patients with macroadenoma, the corresponding values were 3885 ± 5077 mm 3 at baseline and 2723 ± 3435 and 2406 ± 3207 mm 3 after 24 and 48 weeks, respectively. At weeks 24 and 48, a significant (> 20%) tumour volume reduction was reported in 63% and 75% of patients, respectively. A reduction in the severity of symptoms of acromegaly was observed early in treatment and was maintained throughout the study period. Conclusion Octreotide LAR represents a viable alternative to surgery for primary treatment of acromegaly leading to a progressive regression of tumour volume, a sustained control of biochemical abnormalities and an adequate relief of symptoms of the disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2265.2007.02825.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 214

Metadata

Authors
Mercado, M., Borges, F., Bouterfa, H., Chang, T., Chervin, A., Farrall, A. J., Patocs, A., Petersenn, S., Podoba, J., Safari, M., Wardlaw, J., & on behalf of the SMS995B2401 Study Group
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2007-04-25
Volume
66
Issue
6
Pages
859-868
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2169614922
Cited by
214
References
0
FWCI
11.57
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegaly. https://app.cochat.ai/papers/10.1111/j.1365-2265.2007.02825.x
The paper
Mercado, M., Borges, F., Bouterfa, H., Chang, T., Chervin, A., Farrall, A. J., Patocs, A., Petersenn, S., Podoba, J., Safari, M., Wardlaw, J., & on behalf of the SMS995B2401 Study Group. (2007). A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.2007.02825.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.